Atlas Trials

PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer

Clinical trial NCT07130344 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07130344
Sponsor
Centre Paul Strauss
Status
NOT_YET_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Metastatic Breast CancerHER 2 Low-expressing Breast Cancer
Start date
2025-09-01
Primary completion
2028-12-01
Enrollment
262

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.